PlainRecalls
FDA Drug Moderate Class II Ongoing

Aurobindo Ranitidine Capsules 150 mg, 500 count bottle, Rx Only Distributed by: Aurobindo Pharma USA, Inc. 279 Princeton-Hightstown Road East Windsor, NJ 08520 NDC 59651-144-05

Reported: December 4, 2019 Initiated: November 6, 2019 #D-0530-2020

Product Description

Aurobindo Ranitidine Capsules 150 mg, 500 count bottle, Rx Only Distributed by: Aurobindo Pharma USA, Inc. 279 Princeton-Hightstown Road East Windsor, NJ 08520 NDC 59651-144-05

Reason for Recall

CGMP Deviations: N-nitrosodimethylamine (NDMA) has been detected in Ranitidine tablets, capsules and syrups.

Details

Recalling Firm
AuroMedics Pharma LLC
Units Affected
26,736 bottles
Distribution
nationwide
Location
East Windsor, NJ

Frequently Asked Questions

What product was recalled?
Aurobindo Ranitidine Capsules 150 mg, 500 count bottle, Rx Only Distributed by: Aurobindo Pharma USA, Inc. 279 Princeton-Hightstown Road East Windsor, NJ 08520 NDC 59651-144-05. Recalled by AuroMedics Pharma LLC. Units affected: 26,736 bottles.
Why was this product recalled?
CGMP Deviations: N-nitrosodimethylamine (NDMA) has been detected in Ranitidine tablets, capsules and syrups.
Which agency issued this recall?
This recall was issued by the FDA Drug on December 4, 2019. Severity: Moderate. Recall number: D-0530-2020.